M. Rabinowitz, A. Mangalik, F. Lee, C. Jennings, A. Parsons, C. Verschraegen, M. Royce, I. Rabinowitz
Most patients with breast cancer receive anthracyclines and taxanes in either the adjuvant or metastatic setting. Carboplatin, vinorelbine and capecitabine each has single agent activity in breast cancer. In addition they are non-cross resistant and generally have non-overlapping toxicities. The purpose of this study is to assess the response rate of this triplet combination in women with metastatic breast cancer previously treated with anthracycline and taxane based chemotherapy. The dosing schedule was carboplatin 300mg/m2 day 1, vinorelbine 25mg/m2 day 1 & 8 and capecitabine 1500mg/m2/day on days 1-14 every 21 days. Twenty three patients were evaluable for both efficacy and toxicities. Seventy eight percent of patients had refractory disease. The overall response rate was 65%. Complete responses were observed in 13%, and partial responses in 52%. The median progression free survival was 5.5 months. The Kaplan-Meier estimated median survival was 17.5 months. Two patients (8%) progressed on chemotherapy and 43% of patients received additional systemic therapy following participation in this study. Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 30%, 7% and 5% of 128 cycles, respectively. Thirty seven percent of cycles required G-CSF support. One patient died of respiratory failure, possibly related to treatment. The regimen of carboplatin, vinorelbine and capecitabine has significant activity in this refractory heavily pretreated population, making it a promising therapeutic option in women with metastatic breast cancer.
{"title":"Phase II Study of Carboplatin, Vinorelbine and Capecitabine in Patients with Metastatic Breast Cancer","authors":"M. Rabinowitz, A. Mangalik, F. Lee, C. Jennings, A. Parsons, C. Verschraegen, M. Royce, I. Rabinowitz","doi":"10.5580/10e2","DOIUrl":"https://doi.org/10.5580/10e2","url":null,"abstract":"Most patients with breast cancer receive anthracyclines and taxanes in either the adjuvant or metastatic setting. Carboplatin, vinorelbine and capecitabine each has single agent activity in breast cancer. In addition they are non-cross resistant and generally have non-overlapping toxicities. The purpose of this study is to assess the response rate of this triplet combination in women with metastatic breast cancer previously treated with anthracycline and taxane based chemotherapy. The dosing schedule was carboplatin 300mg/m2 day 1, vinorelbine 25mg/m2 day 1 & 8 and capecitabine 1500mg/m2/day on days 1-14 every 21 days. Twenty three patients were evaluable for both efficacy and toxicities. Seventy eight percent of patients had refractory disease. The overall response rate was 65%. Complete responses were observed in 13%, and partial responses in 52%. The median progression free survival was 5.5 months. The Kaplan-Meier estimated median survival was 17.5 months. Two patients (8%) progressed on chemotherapy and 43% of patients received additional systemic therapy following participation in this study. Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 30%, 7% and 5% of 128 cycles, respectively. Thirty seven percent of cycles required G-CSF support. One patient died of respiratory failure, possibly related to treatment. The regimen of carboplatin, vinorelbine and capecitabine has significant activity in this refractory heavily pretreated population, making it a promising therapeutic option in women with metastatic breast cancer.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86491281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Mustapha, M. T. Bolori, N. Ajayi, H. Nggada, U. Pindiga, W. Gashau, M. Khalil
Objective: The aim of the study is to determine the frequency of antibodies to hepatitis C virus among Nigerian patients with hepatocellular carcinoma. Method: The study was prospective. Patients with histologically confirmed hepatocellular carcinoma were studied. Sera of the patients were tested for hepatitis C virus antibodies using a third generation ELISA. Results: A total of 108 patients consisting of 81 males and 27 females were studied, giving a male to female ratio of 4:1. Their ages ranged from 22 to 75 years with a mean of 48 years (SD±13.0). The highest incidence of hepatocellular carcinoma was found among those aged 4049 years. A total of 19 patients (17.6%) were positive for HCV antibodies. There was no significant difference in the frequencies of these antibodies between the male and female patients. Conclusion: HCV plays a significant role in the etiology of hepatocellular carcinoma in Nigeria. Therefore, patients with chronic hepatitis C should be screened for HCC on regular basis.
{"title":"Hepatitis C Virus Antibodies In Nigerians With Hepatocellular Carcinoma","authors":"S. Mustapha, M. T. Bolori, N. Ajayi, H. Nggada, U. Pindiga, W. Gashau, M. Khalil","doi":"10.5580/1669","DOIUrl":"https://doi.org/10.5580/1669","url":null,"abstract":"Objective: The aim of the study is to determine the frequency of antibodies to hepatitis C virus among Nigerian patients with hepatocellular carcinoma. Method: The study was prospective. Patients with histologically confirmed hepatocellular carcinoma were studied. Sera of the patients were tested for hepatitis C virus antibodies using a third generation ELISA. Results: A total of 108 patients consisting of 81 males and 27 females were studied, giving a male to female ratio of 4:1. Their ages ranged from 22 to 75 years with a mean of 48 years (SD±13.0). The highest incidence of hepatocellular carcinoma was found among those aged 4049 years. A total of 19 patients (17.6%) were positive for HCV antibodies. There was no significant difference in the frequencies of these antibodies between the male and female patients. Conclusion: HCV plays a significant role in the etiology of hepatocellular carcinoma in Nigeria. Therefore, patients with chronic hepatitis C should be screened for HCC on regular basis.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90003574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Konstantinidis, Theano T. Pissanidou, A. Sioga, L. Economou, C. Demertzidis, N. Pissanidis
Background: Early induction of chemotherapy in patients operated for colorectal carcinomas, may cause a significant delay in wound healing and multiply the risk of septic complications. Capecitabine is a new fluoropyrimidine carbamate with antineoplastic activity, indicated for the therapy of colorectal cancer. The impact of capecitabine administration during the perioperative period after colectomy was studied. Methods: Rats, which underwent colectomy and hand sutured colonic anastomosis, were pretreated with capecitabine. Sixty Wistar rats where randomized in two groups of 30 rats each. In the study group capecitabine was administered at therapeutic dose, from 1 week prior the operation throughout the study. Control group received placebo. Rats were sacrificed in groups of 10 animals on the 3, 7 and 14 postoperative days, in both experimental and control groups. Results: All animals of the experimental group gained weight postoperatively. No negative impact on the healing of experimental animal's colonic anastomoses was reported. The median bursting pressure was found to be significantly higher and histological findings showed less necrotic effects in experimental animals sacrificed on the 3 day, in comparison to controls. Conclusions: Administration of capecitabine during colectomy does not have a negative impact on the recovery of preoperatively treated animals, neither on the healing of colonic anastomoses.
{"title":"Capecitabine Provides Low Toxicity Antitumor Chemotherapy During Perioperative Period Of Colectomy: Experimental Study In Rats","authors":"H. Konstantinidis, Theano T. Pissanidou, A. Sioga, L. Economou, C. Demertzidis, N. Pissanidis","doi":"10.5580/1043","DOIUrl":"https://doi.org/10.5580/1043","url":null,"abstract":"Background: Early induction of chemotherapy in patients operated for colorectal carcinomas, may cause a significant delay in wound healing and multiply the risk of septic complications. Capecitabine is a new fluoropyrimidine carbamate with antineoplastic activity, indicated for the therapy of colorectal cancer. The impact of capecitabine administration during the perioperative period after colectomy was studied. Methods: Rats, which underwent colectomy and hand sutured colonic anastomosis, were pretreated with capecitabine. Sixty Wistar rats where randomized in two groups of 30 rats each. In the study group capecitabine was administered at therapeutic dose, from 1 week prior the operation throughout the study. Control group received placebo. Rats were sacrificed in groups of 10 animals on the 3, 7 and 14 postoperative days, in both experimental and control groups. Results: All animals of the experimental group gained weight postoperatively. No negative impact on the healing of experimental animal's colonic anastomoses was reported. The median bursting pressure was found to be significantly higher and histological findings showed less necrotic effects in experimental animals sacrificed on the 3 day, in comparison to controls. Conclusions: Administration of capecitabine during colectomy does not have a negative impact on the recovery of preoperatively treated animals, neither on the healing of colonic anastomoses.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75820725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Prabhakar, T. Ganesh, R. Joshi, M. Malik, P. Julka, G. Rath
2-Dimensional radiotherapy treatment planning continues to be widely used for various treatment sites in developing countries due to resource constraints. This has significant effects and treatment volumes and consequently outcomes. In this study, an attempt has been made to quantify the variations in the isocenter position in 2-dimensional radiotherapy planning compared with 3-Dimensional radiotherapy planning for various common treatment sites. It was seen that the variation was maximum in treatment planning of the breast.
{"title":"Quantification Of Shift In Isocenter For 2-Dimensional And 3-Dimensional Radiotherapy Plans For Various Common Treatment Sites","authors":"R. Prabhakar, T. Ganesh, R. Joshi, M. Malik, P. Julka, G. Rath","doi":"10.5580/2323","DOIUrl":"https://doi.org/10.5580/2323","url":null,"abstract":"2-Dimensional radiotherapy treatment planning continues to be widely used for various treatment sites in developing countries due to resource constraints. This has significant effects and treatment volumes and consequently outcomes. In this study, an attempt has been made to quantify the variations in the isocenter position in 2-dimensional radiotherapy planning compared with 3-Dimensional radiotherapy planning for various common treatment sites. It was seen that the variation was maximum in treatment planning of the breast.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78914791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This review is a retrospective Meta analysis of 3133 patients evaluating injection techniques for breast lymphoscintigraphy in patients with early stage breast cancer. The optimal protocol for breast lymphoscintigraphy in early breast cancer patients was shown to employ areolar injection methods of radiocolloid over both blue dye and combined radiocolloid/blue dye techniques.
{"title":"Injection Techniques For Breast Lymphoscintigraphy: A Review","authors":"Sarah Davey, S. White, G. Currie, Janelle Wheat","doi":"10.5580/65","DOIUrl":"https://doi.org/10.5580/65","url":null,"abstract":"This review is a retrospective Meta analysis of 3133 patients evaluating injection techniques for breast lymphoscintigraphy in patients with early stage breast cancer. The optimal protocol for breast lymphoscintigraphy in early breast cancer patients was shown to employ areolar injection methods of radiocolloid over both blue dye and combined radiocolloid/blue dye techniques.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73698434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dennie V. Jones, Souzan Sanati, A. Haque, D. Freeman, I. Kessel, J. Zwischenberger, Jingwu Xie
In nonsmall cell lung cancer (NSCLC), prognostic factors have been established including tumor stage and performance status, however, survival within the same stage is variable and additional prognostic factors are needed. We investigated a microarray of paraffin-embedded sections from 108 cases of NSCLC which were immunostained with monoclonal antibodies against Ki-67, FRAP, HER2, PTEN, VEGF, COX-2, CD117, and PDGF, using an enhanced sensitivity avidin-biotin peroxidase technique. Staining was graded as a percentage of positive cells, and results correlated with survival by log-rank test and Kaplan Meier survival plots. Improved survival was correlated with female gender, squamous cell histology, low Ki67 expression, and lack of FRAP expression. VEGF and CD117 expression was correlated with stage, while COX2 expression showed significant differences by ethnicity. There was no statistical difference between the staining patterns of HER2, PTEN, and PDGF by pathologic factor, patient demographics, or survival outcome.
{"title":"The Expression Of Signal Transduction Proteins And Their Relationship To Clinical Findings In Patients With Nonsmall Cell Lung Cancer","authors":"Dennie V. Jones, Souzan Sanati, A. Haque, D. Freeman, I. Kessel, J. Zwischenberger, Jingwu Xie","doi":"10.5580/ecd","DOIUrl":"https://doi.org/10.5580/ecd","url":null,"abstract":"In nonsmall cell lung cancer (NSCLC), prognostic factors have been established including tumor stage and performance status, however, survival within the same stage is variable and additional prognostic factors are needed. We investigated a microarray of paraffin-embedded sections from 108 cases of NSCLC which were immunostained with monoclonal antibodies against Ki-67, FRAP, HER2, PTEN, VEGF, COX-2, CD117, and PDGF, using an enhanced sensitivity avidin-biotin peroxidase technique. Staining was graded as a percentage of positive cells, and results correlated with survival by log-rank test and Kaplan Meier survival plots. Improved survival was correlated with female gender, squamous cell histology, low Ki67 expression, and lack of FRAP expression. VEGF and CD117 expression was correlated with stage, while COX2 expression showed significant differences by ethnicity. There was no statistical difference between the staining patterns of HER2, PTEN, and PDGF by pathologic factor, patient demographics, or survival outcome.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74643822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Human prostate mortality is associated with tumor invasion and metastasis. In this study, we examined the consequences of overexpression of pigment epithelium-derived factor (PEDF) on both prostate cancer primary tumor growth and metastasis development. Methods: In vivo, the prostate cancer cells DU145 with overexpression of PEDF were injected s.c. into SCID mice. The tumor volume (mm 3 ) was measured by applying the formula [volume = 0.52 × (width) 2 × (length)] for approximating the volume of a spheroid, and lung metastases are evaluated using India ink staining. Intratumoral microvessel density (MVD) was detected by immunohistochemistry using mouse anti-human CD31 monoclonal antibody. Human microvessel endothelial cells (HMVEC) tube formation was assayed in vitro. Secreted VEGF was determined by ELISA. Results: The growth of implanted tumor was significantly reduced in sizes, and the lung metastases were also completely inhibited. Compared to control, MVD decreased significantly in the mice transfected with PEDF [(31 ± 3.25) versus (14.25 ± 3.40) (p < 0.01)]. Furthermore, PEDF overexpression also greatly inhibited tube formation in vitro, and decreased production of VEGF in DU145 cells. Conclusions: It was suggested that the effects of PEDF on primary tumor growth and lung metastasis appear associated with inhibition of angiogenic tumor response. PEDF-mediated inhibition of prostate cancer growth and metastases could thus have a major impact on existing therapies for prostate cancer.
{"title":"Inhibition of Human Prostate Cancer Growth and Prevention of Metastasis Development by Antiangiogenic Activities of Pigment Epithelium-Derived Factor","authors":"W. Su, Qiyu Wang","doi":"10.5580/15b4","DOIUrl":"https://doi.org/10.5580/15b4","url":null,"abstract":"Background: Human prostate mortality is associated with tumor invasion and metastasis. In this study, we examined the consequences of overexpression of pigment epithelium-derived factor (PEDF) on both prostate cancer primary tumor growth and metastasis development. Methods: In vivo, the prostate cancer cells DU145 with overexpression of PEDF were injected s.c. into SCID mice. The tumor volume (mm 3 ) was measured by applying the formula [volume = 0.52 × (width) 2 × (length)] for approximating the volume of a spheroid, and lung metastases are evaluated using India ink staining. Intratumoral microvessel density (MVD) was detected by immunohistochemistry using mouse anti-human CD31 monoclonal antibody. Human microvessel endothelial cells (HMVEC) tube formation was assayed in vitro. Secreted VEGF was determined by ELISA. Results: The growth of implanted tumor was significantly reduced in sizes, and the lung metastases were also completely inhibited. Compared to control, MVD decreased significantly in the mice transfected with PEDF [(31 ± 3.25) versus (14.25 ± 3.40) (p < 0.01)]. Furthermore, PEDF overexpression also greatly inhibited tube formation in vitro, and decreased production of VEGF in DU145 cells. Conclusions: It was suggested that the effects of PEDF on primary tumor growth and lung metastasis appear associated with inhibition of angiogenic tumor response. PEDF-mediated inhibition of prostate cancer growth and metastases could thus have a major impact on existing therapies for prostate cancer.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79309899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Stelzer, A. Mesiwala, Farrokh R. Farrokhi, D. Silbergeld
Objective and Importance: Brachytherapy with the GliaSite balloon system, is a recently-developed treatment option for recurrent malignant glioma. We report a complication with the intent of supplementing the limited published clinical experience with this device. Clinical Presentation: Following resection of recurrent glioblastoma in the right temporal lobe of a 66 year-old man, a GliaSiteTM balloon was implanted. Ninety minutes postoperatively, the patient developed left hemiparesis. Imaging revealed an acute infarct within the distribution of the right posterior cerebral artery. Technique: Prior reported clinical experiences were explored to elucidate the potential frequency of neurological deficits associated with balloon inflation, with emphasis on the relative geometries of the balloon and resection cavity. Conclusion: Risk of acute neurological deficits and possible stroke may be underappreciated with the GliaSiteTM system. Additional investigations into the pressure-volume relationships as a function of resection cavity deviation from spherical shape may be helpful in patient selection and device utilization. OBJECTIVE AND IMPORTANCE Despite advances in surgery, radiation, and chemotherapy, long-term survival of patients with glioblastoma multiforme (GBM) remains poor, with the vast majority of patients suffering recurrent tumor. Options for treating recurrent GBM include surgery, chemotherapy (systemic or implanted), and/or radiation. Retreatment with radiation requires focal therapy to minimize the volume of normal brain tissue receiving high cumulative doses. Consequently, various forms of brachytherapy have been used to administer radiation in the setting of recurrent GBM. Recently, brachytherapy using the GliaSiteTM (Proxima Therapeutics Inc., Alpharetta, Georgia, USA) intra-cavitary radiation system has been reported for recurrent malignant glioma.1,2 The GliaSiteTM device consists of a silicone balloon that comes in a variety of sizes which can be intraoperatively fitted to relatively spherical resection cavities. The device is then after-loaded by filling with an aqueous iodine-125 solution. Consistent spatial localization of the radiation dose is achievable with this relatively rigid spherical balloon system.3 We present a complication associated with use of this system that may be more common than previously recognized. CLINICAL PRESENTATION A 66 year-old man presented for resection of a recurrent right temporal GBM (Figure 1). Posterior Cerebral Artery Compression and Subsequent Infarction after Implantation of a GliaSiteTM Balloon
{"title":"Posterior Cerebral Artery Compression and Subsequent Infarction after Implantation of a GliaSite™ Balloon","authors":"K. Stelzer, A. Mesiwala, Farrokh R. Farrokhi, D. Silbergeld","doi":"10.5580/16f9","DOIUrl":"https://doi.org/10.5580/16f9","url":null,"abstract":"Objective and Importance: Brachytherapy with the GliaSite balloon system, is a recently-developed treatment option for recurrent malignant glioma. We report a complication with the intent of supplementing the limited published clinical experience with this device. Clinical Presentation: Following resection of recurrent glioblastoma in the right temporal lobe of a 66 year-old man, a GliaSiteTM balloon was implanted. Ninety minutes postoperatively, the patient developed left hemiparesis. Imaging revealed an acute infarct within the distribution of the right posterior cerebral artery. Technique: Prior reported clinical experiences were explored to elucidate the potential frequency of neurological deficits associated with balloon inflation, with emphasis on the relative geometries of the balloon and resection cavity. Conclusion: Risk of acute neurological deficits and possible stroke may be underappreciated with the GliaSiteTM system. Additional investigations into the pressure-volume relationships as a function of resection cavity deviation from spherical shape may be helpful in patient selection and device utilization. OBJECTIVE AND IMPORTANCE Despite advances in surgery, radiation, and chemotherapy, long-term survival of patients with glioblastoma multiforme (GBM) remains poor, with the vast majority of patients suffering recurrent tumor. Options for treating recurrent GBM include surgery, chemotherapy (systemic or implanted), and/or radiation. Retreatment with radiation requires focal therapy to minimize the volume of normal brain tissue receiving high cumulative doses. Consequently, various forms of brachytherapy have been used to administer radiation in the setting of recurrent GBM. Recently, brachytherapy using the GliaSiteTM (Proxima Therapeutics Inc., Alpharetta, Georgia, USA) intra-cavitary radiation system has been reported for recurrent malignant glioma.1,2 The GliaSiteTM device consists of a silicone balloon that comes in a variety of sizes which can be intraoperatively fitted to relatively spherical resection cavities. The device is then after-loaded by filling with an aqueous iodine-125 solution. Consistent spatial localization of the radiation dose is achievable with this relatively rigid spherical balloon system.3 We present a complication associated with use of this system that may be more common than previously recognized. CLINICAL PRESENTATION A 66 year-old man presented for resection of a recurrent right temporal GBM (Figure 1). Posterior Cerebral Artery Compression and Subsequent Infarction after Implantation of a GliaSiteTM Balloon","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76586723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: “Hockey stick” irradiation is the classical adjuvant treatment for patients with stage I testicular seminoma after orchiectomy, resulting in 98-99% long-term disease free survival. This treatment option has been recently challenged by two alternative approaches a) observation only or b) adjuvant chemotherapy. One of the concerns raised against radiotherapy has been an increased risk of infertility. Impaired spermatogenesis due to scattered and transmitted irradiation to the remaining testicle has been reported in several studies. Although recovery of sperm cell production is observed in most patients, long term oligospermia or azospermia remains an important concern in these mostly young patients. Patients / Methods: We conducted a retrospective study addressing the question of paternity post “hockey stick” irradiation. We reviewed the medical records of 36 patients with stage I seminoma who received post-orchiectomy irradiation at Hadassah University Hospital between January 1994 and September 2004. Patients were contacted by telephone and interviewed regarding paternity status, fertility problems and any need for assisted reproduction treatments. Results: All patients were treated on a high energy linear accelerator with “hockey stick” field to a dose of 22.5-24 Gy in 1.5 Gy fractions with an AP-PA technique. A testicular shell was always used. Semen preservation was recommended to all patients. With a median follow up of 88 months, no patient developed disease recurrence and the only second primary tumor observed was one contralateral testicular germ cell tumor. 13 of the 36 patients were older than 40 years of age and had children at the time of diagnosis, and did not attempt to have further children. One patient was known to be oligospermic and one was azospermic prior to diagnosis. 5 patients were lost to follow-up. Of the 15 patients left, 5 have not yet "tested" their fertility. The 10 who have tried to conceive succeeded with no need for any interventions. 5 of them have each 2 children born after treatment, the other 5 have each one child. The patient with oligospermia had a successful IVF. Conclusions: In our experience, patients treated with adjuvant post-orchiectomy “hockey stick” radiotherapy preserved their fertility. None of those who wanted to reproduce needed any intervention.
{"title":"Fertility After Adjuvant External Beam Radiotherapy For Stage I Seminoma","authors":"O. Gutfeld, M. Wygoda, L. Shavit, T. Grenader","doi":"10.5580/2188","DOIUrl":"https://doi.org/10.5580/2188","url":null,"abstract":"Introduction: “Hockey stick” irradiation is the classical adjuvant treatment for patients with stage I testicular seminoma after orchiectomy, resulting in 98-99% long-term disease free survival. This treatment option has been recently challenged by two alternative approaches a) observation only or b) adjuvant chemotherapy. One of the concerns raised against radiotherapy has been an increased risk of infertility. Impaired spermatogenesis due to scattered and transmitted irradiation to the remaining testicle has been reported in several studies. Although recovery of sperm cell production is observed in most patients, long term oligospermia or azospermia remains an important concern in these mostly young patients. Patients / Methods: We conducted a retrospective study addressing the question of paternity post “hockey stick” irradiation. We reviewed the medical records of 36 patients with stage I seminoma who received post-orchiectomy irradiation at Hadassah University Hospital between January 1994 and September 2004. Patients were contacted by telephone and interviewed regarding paternity status, fertility problems and any need for assisted reproduction treatments. Results: All patients were treated on a high energy linear accelerator with “hockey stick” field to a dose of 22.5-24 Gy in 1.5 Gy fractions with an AP-PA technique. A testicular shell was always used. Semen preservation was recommended to all patients. With a median follow up of 88 months, no patient developed disease recurrence and the only second primary tumor observed was one contralateral testicular germ cell tumor. 13 of the 36 patients were older than 40 years of age and had children at the time of diagnosis, and did not attempt to have further children. One patient was known to be oligospermic and one was azospermic prior to diagnosis. 5 patients were lost to follow-up. Of the 15 patients left, 5 have not yet \"tested\" their fertility. The 10 who have tried to conceive succeeded with no need for any interventions. 5 of them have each 2 children born after treatment, the other 5 have each one child. The patient with oligospermia had a successful IVF. Conclusions: In our experience, patients treated with adjuvant post-orchiectomy “hockey stick” radiotherapy preserved their fertility. None of those who wanted to reproduce needed any intervention.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74246484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Shankar, Satyendra K. Satyendra, R. Khanna, M. Kumar, A. Khanna
Introduction: Angiogenesis is an important new prognostic indicator in breast cancer. Several works have been devoted to study the tumor angiogenesis asMicrovessel density, Doppler study, VEGF expression but all these techniques are expensive and require special laboratory to measure them. Microscopic Angiogenesis Grading System (MAGS) is an easy technique, can be carried out by any expert pathologist and does not require any extra preparation and needsonly H and E staining study which can be done in every biopsy specimen. Material and Method: 30 cases of carcinoma breast and 10 cases of fibroadenoma underwent MAGS scoring by looking for Vasoproliferation (N), Endothelial Cell Hyperplasia (E) and Endothelial Cytology (X). and score was calculated as MAGS SCORE = KnN + KeE + KxX Results: Higher MAGS score was associated with advanced stage, higher grade and lymph node positive tumors(p<0.05). Conclusion: MAGS score is a good marker of tumor angiogenesis for prognostication in carcinoma breast and it is a marker of poor prognosis.
{"title":"MAGS Scoring: A Marker Of Tumor Angiogenesis And Prognostic Indicator In Carcinoma Breast","authors":"R. Shankar, Satyendra K. Satyendra, R. Khanna, M. Kumar, A. Khanna","doi":"10.5580/172f","DOIUrl":"https://doi.org/10.5580/172f","url":null,"abstract":"Introduction: Angiogenesis is an important new prognostic indicator in breast cancer. Several works have been devoted to study the tumor angiogenesis asMicrovessel density, Doppler study, VEGF expression but all these techniques are expensive and require special laboratory to measure them. Microscopic Angiogenesis Grading System (MAGS) is an easy technique, can be carried out by any expert pathologist and does not require any extra preparation and needsonly H and E staining study which can be done in every biopsy specimen. Material and Method: 30 cases of carcinoma breast and 10 cases of fibroadenoma underwent MAGS scoring by looking for Vasoproliferation (N), Endothelial Cell Hyperplasia (E) and Endothelial Cytology (X). and score was calculated as MAGS SCORE = KnN + KeE + KxX Results: Higher MAGS score was associated with advanced stage, higher grade and lymph node positive tumors(p<0.05). Conclusion: MAGS score is a good marker of tumor angiogenesis for prognostication in carcinoma breast and it is a marker of poor prognosis.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2005-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76790399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：